BA
MRNA icon

Birinyi Associates’s Moderna MRNA Stock Holding History

Birinyi Associates’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,250
Closed -$571K – 62
2021
Q4 		$571K Sell
2,250
-2,400
-52% -$702K 0.18% 46
2021
Q3 		$1.79M Buy
4,650
+2,150
+86% +$793K 0.6% 30
2021
Q2 		$587K Sell
2,500
-1,100
-31% -$197K 0.2% 47
2021
Q1 		$471K Buy
+3,600
New +$522K 0.18% 53

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Birinyi Associates's MRNA Position: Q1 2022 in Review

Birinyi Associates sold out of Moderna (MRNA) in Q1 2022, closing a stake of 2,250 shares — an estimated $571K sold.

Birinyi Associates first reported a position in MRNA in Q1 2021 and held it in 4 quarters. The position peaked at $1.79M in Q3 2021. 1,006 funds tracked by Wall St. Rank hold MRNA as of Q1 2022.

  • Birinyi Associates reported no remaining Moderna position as of Q1 2022 after selling out during the quarter.
  • Birinyi Associates sold 2,250 Moderna shares in Q1 2022, an estimated $571K.
  • Birinyi Associates first reported a position in Moderna in Q1 2021 and held it in 4 quarters.
  • Birinyi Associates's Moderna position peaked at $1.79M in Q3 2021.
  • 1,006 funds tracked by Wall St. Rank held Moderna as of Q1 2022.

Based on Birinyi Associates's 13F filing for Q1 2022, filed 5 Apr 2022.